Quintiles Extends Phase I Capacity and Capabilities
Quintiles announced the opening of its expanded research facility in London, UK, designed to increase Phase I capacity and extend its ability to drive progress in translational medicine. The facility is housed on the 14th floor of Guy's Hospital, adjacent to a Biomedical Research Centre (BRC).
With capacity for 35 patients and healthy volunteers, the extension brings the total number of Phase I beds in London to 105 and globally to 385. This is expected to increase further in late 2010, with the opening of a Phase I unit in Hyderabad, India, initially with 50 beds, and with capacity for expansion to 100.
“Declining productivity in research and development means that the biopharmaceutical industry is under intense pressure to increase efficiency and overcome complexity,” explains Eddie Caffrey, Senior Vice President, Global Phase I at Quintiles.
“Effective early-stage development can have significant impact on speed and cost of the overall development process. Our customers need a holistic solution that combines fast and cost-efficient regulatory studies with advanced scientific expertise and techniques such as modeling and simulation, biomarkers and microdosing for more complex studies."
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
